Abstract
Pharmacologic treatment of myocardial ischemia in patients with chronic stable angina (CSA) is mainly based on heart rate lowering drugs and vasodilator agents. Other drugs are available, however, that act by some peculiar mechanism (ranolazine, trimetazidine) and may add potential anti-ischemic and anti-anginal effects to standard therapeutic mechanisms. While anti-ischemic agents are crucial for controlling angina symptoms and improving quality of life, whether myocardial ischemia portends an ominous prognosis and its suppression improves clinical outcome in CSA patients remain debated issues.
| Original language | English |
|---|---|
| Pages (from-to) | 341-349 |
| Number of pages | 9 |
| Journal | Cardiovascular Drugs and Therapy |
| Volume | 30 |
| DOIs | |
| Publication status | Published - 2016 |
Keywords
- Angina
- Cardiology and Cardiovascular Medicine
- Cardiovascular Agents
- Clinical outcome
- Heart Rate
- Humans
- Medical therapy
- Myocardial Ischemia
- Myocardial ischemia
- Pathophysiologic mechanisms
- Pharmacology
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Overview of Management of Myocardial Ischemia: a Mechanistic-Based Approach'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver